NCT02105688View on ClinicalTrials.gov

An Efficacy and Safety Study of Grazoprevir (MK-5172) + Elbasvir (MK-8742) in the Treatment of Chronic Hepatitis C Virus (HCV) Genotype (GT)1, 4, or 6 Infection in Treatment-Naïve Participants Who Are on Opiate Substitution Therapy (MK-5172-062)

PHASE3CompletedINTERVENTIONAL

Enrollment

301

Participants

Timeline

Start Date

September 2, 2014

Primary Completion Date

June 10, 2015

Study Completion Date

December 4, 2018

Conditions

Chronic Hepatitis C

Interventions

DRUG

Grazoprevir 100 mg/Elbasvir 50 mg FDC tablet (MK-5172A)

Grazoprevir 100 mg/Elbasvir 50 mg FDC tablet, taken once daily by mouth for 12 weeks.

DRUG

Placebo to Grazoprevir 100 mg/Elbasvir 50 mg FDC tablet

Placebo Grazoprevir 100 mg/Elbasvir 50 mg FDC tablet, taken once daily by mouth for 12 weeks.

All Listed Sponsors

lead

Merck Sharp & Dohme LLC

INDUSTRY

NCT02105688 - An Efficacy and Safety Study of Grazoprevir (MK-5172) + Elbasvir (MK-8742) in the Treatment of Chronic Hepatitis C Virus (HCV) Genotype (GT)1, 4, or 6 Infection in Treatment-Naïve Participants Who Are on Opiate Substitution Therapy (MK-5172-062) | Biotech Hunter | Biotech Hunter